The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 27, 2020

Filed:

Apr. 10, 2019
Applicant:

Abiogen Pharma S.p.a., Pisa, IT;

Inventors:

Laura Dini, Pisa, IT;

Fabio Neggiani, Pisa, IT;

Barbara Politi, Leghorn, IT;

Stefano Luca Giaffreda, Bologna, IT;

Alex Petrolati, Senigallia, IT;

Michel Chiarucci, Castenaso, IT;

Serena Fabbroni, Medicina, IT;

Kesheng Zhang, Lenzburg, CH;

Michael Roeder, Gomaringen, DE;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07F 9/38 (2006.01); A61P 5/20 (2006.01); A61P 19/02 (2006.01); A61P 3/14 (2006.01); A61P 35/04 (2006.01); A61P 19/10 (2006.01); C07F 9/02 (2006.01); A61K 31/663 (2006.01);
U.S. Cl.
CPC ...
C07F 9/3873 (2013.01); A61K 31/663 (2013.01); A61P 3/14 (2018.01); A61P 5/20 (2018.01); A61P 19/02 (2018.01); A61P 19/10 (2018.01); A61P 35/04 (2018.01); C07F 9/025 (2013.01); C07B 2200/13 (2013.01);
Abstract

The present invention relates to a novel crystalline hemihydrate polymorph of neridronic acid sodium salt, and a novel process for the preparation thereof comprising the steps of: 1) dissolving solid sodium neridronate in any crystalline form in water, at a temperature in the range from 70 to 90° C., to obtain an aqueous solution of sodium neridronate; 2) adding a solvent selected from the group consisting in ethanol, 1-propanol, and 2-propanol to the aqueous solution obtained from step (1), so that the final water:solvent volume ratio is in the range from 1:0.5 to 1:1, thus obtaining a suspension; 3) placing the suspension obtained from step (2) under mechanical stirring, at a temperature in the range from 60 to 95° C.; 4) recovering the crystalline hemihydrate form F of sodium neridronate formed in the previous step (3). The crystalline hemihydrate form F of sodium neridronate, particularly stable, may be employed in the preparation of solid oral pharmaceutical forms for use in the treatment of musculoskeletal and calcium metabolism disorders.


Find Patent Forward Citations

Loading…